Suppr超能文献

新型冠状病毒肺炎对ST段抬高型心肌梗死患者院内结局的影响

The Impact of COVID-19 on In-Hospital Outcomes of ST-Segment Elevation Myocardial Infarction Patients.

作者信息

Ayad Sherif, Shenouda Rafik, Henein Michael

机构信息

Faculty of Medicine, Alexandria University, Alexandria 21526, Egypt.

International Cardiac Center, Alexandria 21526, Egypt.

出版信息

J Clin Med. 2021 Jan 14;10(2):278. doi: 10.3390/jcm10020278.

Abstract

Primary percutaneous coronary intervention (PPCI) is one of the important clinical procedures that have been affected by the COVID-19 pandemic. In this study, we aimed to assess the incidence and impact of COVID-19 on in-hospital clinical outcome of ST elevation myocardial infarction (STEMI) patients managed with PPCI. This observational retrospective study was conducted on consecutive STEMI patients who presented to the International Cardiac Center (ICC) hospital, Alexandria, Egypt between 1 February and 31 October 2020. A group of STEMI patients presented during the same period in 2019 was also assessed (control group) and data was used for comparison. The inclusion criteria were established diagnosis of STEMI requiring PPCI.A total of 634 patients were included in the study. During the COVID-19 period, the number of PPCI procedures was reduced by 25.7% compared with previous year (mean 30.0 ± 4.01 vs. 40.4 ± 5.3 case/month) and the time from first medical contact to Needle (FMC-to-N) was longer (125.0 ± 53.6 vs. 52.6 ± 22.8 min, = 0.001). Also, during COVID-19, the in-hospital mortality was higher (7.4 vs. 4.6%, = 0.036) as was the incidence of re-infarction (12.2 vs. 7.7%, = 0.041) and the need for revascularization (15.9 vs. 10.7%, = 0.046). The incidence of heart failure, stroke, and bleeding was not different between groups, but hospital stay was longer during COVID-19 (6.85 ± 4.22 vs. 3.5 ± 2.3 day, = 0.0025). Conclusion: At the ICC, COVID-19 pandemic contributed significantly to the PPCI management of STEMI patients with decreased number and delayed procedures. COVID-19 was also associated with higher in-hospital mortality, rate of re-infarction, need for revascularization, and longer hospital stay.

摘要

直接经皮冠状动脉介入治疗(PPCI)是受2019冠状病毒病大流行影响的重要临床操作之一。在本研究中,我们旨在评估2019冠状病毒病对接受PPCI治疗的ST段抬高型心肌梗死(STEMI)患者院内临床结局的发生率和影响。本观察性回顾性研究针对2020年2月1日至10月31日期间在埃及亚历山大国际心脏中心(ICC)医院就诊的连续STEMI患者进行。同时评估了2019年同期就诊的一组STEMI患者(对照组),并将数据用于比较。纳入标准为确诊需要PPCI治疗的STEMI。本研究共纳入634例患者。在2019冠状病毒病期间,PPCI手术数量较上一年减少了25.7%(平均每月30.0±4.01例 vs. 40.4±5.3例),从首次医疗接触到穿刺(FMC-to-N)的时间更长(125.0±53.6分钟 vs. 52.6±22.8分钟,P = 0.001)。此外,在2019冠状病毒病期间,院内死亡率更高(7.4% vs. 4.6%,P = 0.036),再梗死发生率(12.2% vs. 7.7%,P = 0.041)和血运重建需求(15.9% vs. 10.7%,P = 0.046)也更高。心力衰竭、中风和出血的发生率在两组之间没有差异,但在2019冠状病毒病期间住院时间更长(6.85±4.22天 vs. 3.5±2.3天,P = 0.0025)。结论:在ICC,2019冠状病毒病大流行对STEMI患者的PPCI治疗产生了重大影响,手术数量减少且手术延迟。2019冠状病毒病还与更高的院内死亡率、再梗死率、血运重建需求和更长的住院时间相关。

相似文献

3
COVID-19 pandemic, mechanical reperfusion and 30-day mortality in ST elevation myocardial infarction.
Heart. 2022 Mar;108(6):458-466. doi: 10.1136/heartjnl-2021-319750. Epub 2021 Oct 28.
4
[Impact of COVID-19 on primary percutaneous coronary intervention in patients with acute ST segment elevation myocardial infarction in Beijing].
Zhonghua Xin Xue Guan Bing Za Zhi. 2023 Sep 24;51(9):977-983. doi: 10.3760/cma.j.cn112148-20230104-00007.
6
[Effect of thrombus aspiration during primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction].
Zhonghua Xin Xue Guan Bing Za Zhi. 2019 Jan 24;47(1):49-55. doi: 10.3760/cma.j.issn.0253-3758.2019.01.006.

引用本文的文献

1
Effect of COVID-19 Pandemic on Acute Coronary Syndrome Clinical Practice Patterns: Findings from a Multicenter Clinician Survey in China.
Rev Cardiovasc Med. 2022 Oct 25;23(11):362. doi: 10.31083/j.rcm2311362. eCollection 2022 Nov.
3
Effect of COVID-19 pandemic on six-month mortality and clinical outcomes of patients with ST-elevation myocardial infarction.
Postepy Kardiol Interwencyjnej. 2022 Sep;18(3):228-236. doi: 10.5114/aic.2022.122864. Epub 2022 Dec 17.
5
The Management of Myocardial Injury Related to SARS-CoV-2 Pneumonia.
J Cardiovasc Dev Dis. 2022 Sep 16;9(9):307. doi: 10.3390/jcdd9090307.
7
The Potential Impact of COVID-19 Virus on the Heart and the Circulatory System.
Infect Drug Resist. 2022 Mar 22;15:1175-1189. doi: 10.2147/IDR.S351318. eCollection 2022.
8
COVID-19 Severity and Cardiovascular Disease: An Inseparable Link.
J Clin Med. 2022 Jan 18;11(3):479. doi: 10.3390/jcm11030479.

本文引用的文献

2
Impact of COVID-19 on percutaneous coronary intervention for ST-elevation myocardial infarction.
Heart. 2020 Dec;106(23):1805-1811. doi: 10.1136/heartjnl-2020-317650. Epub 2020 Aug 31.
3
Management and Outcomes of Patients With STEMI During the COVID-19 Pandemic in China.
J Am Coll Cardiol. 2020 Sep 15;76(11):1318-1324. doi: 10.1016/j.jacc.2020.06.039. Epub 2020 Aug 19.
4
Cardiovascular disease and COVID-19: Australian and New Zealand consensus statement.
Med J Aust. 2020 Aug;213(4):182-187. doi: 10.5694/mja2.50714. Epub 2020 Jul 31.
5
Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era.
Eur Heart J. 2020 Jun 7;41(22):2083-2088. doi: 10.1093/eurheartj/ehaa409.
9
Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States During COVID-19 Pandemic.
J Am Coll Cardiol. 2020 Jun 9;75(22):2871-2872. doi: 10.1016/j.jacc.2020.04.011. Epub 2020 Apr 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验